Literature DB >> 18408595

Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.

Wenle Wang1, Xinlai Sun, Jonathan I Epstein.   

Abstract

Partial atrophy is the most common benign mimicker of prostate cancer on needle biopsy. Of 3916 prostate needle core biopsy cases received in our consultation service over a period of 3 months (March 1, 2007 to May 31, 2007), 170 cases (4.3%) with partial atrophy were diagnosed as atypical glands by outside pathologists and prospectively identified. We supplemented our material with 108 cases of partial atrophy sent to our consultation service in 2006 from a single institution, which frequently uses a triple cocktail stain [p63, high molecular weight cytokeratin (HMWCK), alpha-methyl acyl-Coa racemase (AMACR)]. The morphologic features of the 278 cases and immunohistochemistry of 236 cases (198 with prostate cocktail and 38 with only basal cell makers) were analyzed. Forty-eight of 278 (17.3%) partial atrophy cases were mixed with postatrophic hyperplasia. Enlarged nuclei were visible in 43/278 (15.5%) cases, with prominent nucleoli seen in 58/278 (20.9%) cases (30 cases associated with nuclear enlargement). Of 198 cases with a prostatic cocktail stain, 48 (24.2%) had a cancer pattern for both basal cells and AMACR (p63-, HMWCK-, and AMACR+), 14 (7.1%) had a cancer pattern for basal cells (p63-, HMWCK-, and AMACR-), 89 (44.9%) had a cancer pattern for AMACR (p63+, HMWCK+, and AMACR+), and 47 (23.7%) had a totally benign pattern (p63+, HMWCK+, and AMACR-). Of the 198 cases using the cocktail stain, 136 (68.7%) had positive basal cell staining. The percentage of basal cells labeled with the combination of p63/HMWCK was: <5% in 42 (21.2%) cases, 5% to 75% in 58 (29.3%) cases, and >75% in 36 (18.2%) cases. An additional 38 cases immunostained only for p63 and/or HMWCK was negative in 2 (5.2%) cases, <5% (13.1%) in 5 cases, 5% to 75% in 19 (50%) cases, and >75% in 12 (31.6%) cases. In conclusion, partial atrophy is a benign mimicker of adenocarcinoma both as a result of its routine morphologic features and its immunohistochemical profile. Recognition of the classic morphology of partial atrophy on routine hematoxylin and eosin-stained sections is critical to avoid misdiagnosing partial atrophy as adenocarcinoma.

Entities:  

Mesh:

Year:  2008        PMID: 18408595     DOI: 10.1097/PAS.0b013e31815a0508

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

Review 1.  The benign mimickers of prostatic acinar adenocarcinoma.

Authors:  Yuqiao Xu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Zhe Wang; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

2.  Mergence of partial and complete atrophy in prostate needle biopsies: a morphologic and immunohistochemical study.

Authors:  Athanase Billis; Luciana Meirelles; Leandro L L Freitas
Journal:  Virchows Arch       Date:  2010-04-02       Impact factor: 4.064

3.  α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues.

Authors:  Bin Ouyang; Yuet-Kin Leung; Vinson Wang; Ethan Chung; Linda Levin; Bruce Bracken; Liang Cheng; Shuk-Mei Ho
Journal:  Urology       Date:  2011-01       Impact factor: 2.649

4.  Diagnostic Value of Cytokeratin 34 beta E12 (Ck34βE12) and α-Methylacyl-CoA racemase (AMACR) Immunohistochemical Expression in Prostatic Lesions.

Authors:  Ikram A Hasan; Hiba Ahmed Gaidan; Methaq Mueen Al-Kaabi
Journal:  Iran J Pathol       Date:  2020-05-21

5.  Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Authors:  T Van der Kwast; L Bubendorf; C Mazerolles; M R Raspollini; G J Van Leenders; C-G Pihl; P Kujala
Journal:  Virchows Arch       Date:  2013-08-06       Impact factor: 4.064

Review 6.  [Immunohistochemical algorithms in prostate diagnostics: what's new?].

Authors:  G Kristiansen
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

7.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

8.  p63 is more sensitive and specific than 34βE12 to differentiate adenocarcinoma of prostate from cancer mimickers.

Authors:  Mahmoud Reza Kalantari; Kazem Anvari; Hasan Jabbari; Fatemeh Varshoee Tabrizi
Journal:  Iran J Basic Med Sci       Date:  2014-07       Impact factor: 2.699

9.  Atypical diagnosis in prostate needle biopsies from a developing country (Philippines): The essential role of a urological pathologist.

Authors:  Cecille Marie Julienne B Yañez; Jeffrey S So
Journal:  Prostate Int       Date:  2015-10-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.